AIM ImmunoTech Q2 EPS $(0.10) Beats $(0.11) Estimate; Cash, Cash Equivalents & Marketable Securities Of $28.4M Expected To Provide Cash Runway Into 2024
Portfolio Pulse from Benzinga Newsdesk
AIM ImmunoTech reported Q2 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.11) by 9.09 percent. The company's cash, cash equivalents, and marketable securities of $28.4M are expected to provide a cash runway into 2024.
August 15, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AIM ImmunoTech's Q2 earnings beat estimates, which could positively impact the stock. The company's strong cash position could also provide stability.
AIM ImmunoTech's better-than-expected Q2 earnings and strong cash position could make the stock more attractive to investors, potentially driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100